YAVAPFMC
CMMB

Yahav Achim Ve Achayot - Provident Funds Management Company’s Chemomab Therapeutics CMMB Stock Holding History

Yahav Achim Ve Achayot - Provident Funds Management Company’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-774
Closed -$21K – 57
2021
Q4 		$21K Hold
774
– – 0.02% 55
2021
Q3 		$34K Buy
+774
New +$47.1K 0.03% 53

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Yahav Achim Ve Achayot - Provident Funds Management Company's CMMB Position: Q1 2022 in Review

Yahav Achim Ve Achayot - Provident Funds Management Company sold out of Chemomab Therapeutics (CMMB) in Q1 2022, closing a stake of 774 shares — an estimated $21K sold.

Yahav Achim Ve Achayot - Provident Funds Management Company first reported a position in CMMB in Q3 2021 and held it in 2 quarters. The position peaked at $34K in Q3 2021. 16 funds tracked by Wall St. Rank hold CMMB as of Q1 2022.

  • Yahav Achim Ve Achayot - Provident Funds Management Company reported no remaining Chemomab Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Yahav Achim Ve Achayot - Provident Funds Management Company sold 774 Chemomab Therapeutics shares in Q1 2022, an estimated $21K.
  • Yahav Achim Ve Achayot - Provident Funds Management Company first reported a position in Chemomab Therapeutics in Q3 2021 and held it in 2 quarters.
  • Yahav Achim Ve Achayot - Provident Funds Management Company's Chemomab Therapeutics position peaked at $34K in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2022.

Based on Yahav Achim Ve Achayot - Provident Funds Management Company's 13F filing for Q1 2022, filed 12 May 2022.